All enrolled sufferers who gained no less than just one dose of zosuquidar or placebo during induction were being monitored with the incidence of adverse functions (439 individuals, 219 on zosuquidar and 210 on placebo). The most common adverse situations were related to the duration of prolonged and substantial myelosuppression https://brennusi555ugq7.illawiki.com/user